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THE ASSOCIATION OF CO-MEDICATIONS AND CO-MORBIDITIES AND
RISK OF DEMENTIA, IN PATIENTS WITH CHRONIC HEART FAILURE
Agarwal SJ, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: To determine the association of co-medications and co-morbidities and
the risk of dementia, in patients with chronic heart failure (CHF). METHODS:
A national retrospective cohort of Veterans Affairs (VA) patients, with at least one
outpatient claim of CHF from 1st October 1, 1996 to September 30, 2000, was identi-
ﬁ ed. Drug exposure/co-morbidity data was analyzed from October 1, 1998 to Sep-
tember 30, 2000 and the outcome of dementia (yes/no) was identiﬁ ed based on 
ICD-9-CM codes from October 1, 2000 to September 30, 2002. Patients with non-
utilization of VA services for two years and prevalent cases of dementia were excluded. 
Multivariate logistic regression was conducted to determine outcome estimates, 
adjusted for socio-demographics, co-morbidities and co-medications. RESULTS: Out 
of 242,734 patients, 2.77% met the deﬁ nition for dementia. About 75% were elderly 
and 79% had hypertension. Females, African-Americans had signiﬁ cantly higher risk
of dementia than males, whites, respectively. Risk of dementia increased progressively 
with age. In adjusted analyses, hypertension (OR: 1.172, 95% CI: 1.092–1.259), dia-
betes (OR: 1.085, 95% CI: 1.031–1.142) and seizure (OR: 1.786, 95% CI: 1.598–
1.997) signiﬁ cantly increased the risk of dementia. Adjusted analyses of one-year 
exposure to Angiotensin II Receptor Blockers (ARBs) (OR: 0.785, 95% CI: 0.633–
0.974), digitalis (OR: 0.915, 95% CI: 0.838–0.998) and two-year exposure to ARBs 
(OR: 0.715, 95% CI: 0.595–0.859), statins (OR: 0.909, 95% CI: 0.852–0.971), 
diuretics (OR: 0.877, 95% CI: 0.819–0.938), digitalis (OR: 0.925, 95% CI: 0.868–
0.986) had protective effect on dementia. Adjusted analyses of one-year exposure to 
beta-blockers (OR: 1.077, 95% CI: 1.001–1.159), had increased risk of dementia. 
CONCLUSIONS: This exploratory study highlights that major cardiovascular and
cerebrovascular co-morbidities are signiﬁ cant risk factors for dementia. It indicates
the beneﬁ cial effect of drug classes like ARBs, digitalis, diuretics, and statins. It
provides direction for further evidence based research on patients with multiple co-
morbidities and co-medications.
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DEVELOPMENT OF TESTS FOR EARLY DIAGNOSIS OF PREECLAMPSIA
Schiff L1, Foster T1, Creeden J2, van der Helm W2, Gartemann J2, Pashos CL1
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Roche Diagnostics, Ltd, Rotkreuz, 
Switzerland
OBJECTIVES: Preeclampsia complicates 5–8% of all pregnancies and remains a 
leading cause of maternal and perinatal morbidity and mortality. Negative outcomes 
could be avoided in many patients if a reliable early diagnostic test were available. 
We systematically reviewed the literature to assess the current status of development
of early diagnostic tests for preeclampsia. METHODS: We searched English-language
MEDLINE-indexed publications in the 10 years prior to August 2008 concerning tests 
for early diagnosis of preeclampsia, and literature published in the 5 years prior to
August 2008 using keywords relating to biomarkers for preeclampsia. We also
searched non-MEDLINE-indexed sources such as organization websites, meeting 
abstracts, and governmental publications using the same keywords. RESULTS: We
identiﬁ ed 116 primary studies from MEDLINE pertaining to biomarkers or tests for 
early diagnosis of preeclampsia. Non-MEDLINE sources yielded an additional 2 arti-
cles for a total of 118 reviewed for this study. A variety of serum biomarkers have 
been explored as candidates for predictive diagnostic tests for preeclampsia. These 
biomarkers represent a number of pathological processes involved in preeclampsia, 
including endothelial damage, oxidative stress, altered lipid and glucose metabolism, 
inﬂ ammation, and abnormal immune responses. The angiogenesis-related biomarkers
PlGF and sFlt-1 are at the most advanced state of development as diagnostic tests,
with PlGF decreases and sFlt-1 increases preceding overt clinical symptoms by 5–10
weeks. PlGF has potential to allow screening as early as 14 weeks of gestation, and
sFlt-1 by week 16. Further research is needed to determine whether change in these 
biomarkers predicts preeclampsia or indicates substantially increased risk, or con-
versely, whether lack of change precludes preeclampsia or indicates lower risk. CON-
CLUSIONS: Currently, the angiogenesis-related biomarkers PlGF and sFlt-1 offer the 
most promise for use in the early diagnosis of preeclampsia.
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BURDEN OF HYPERLIPIDEMIA AND ASSOCIATED TREATMENT
PATTERNS IN EUROPE: A COMPARISON OF FIVE COUNTRIES
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany
OBJECTIVES: To assess burden of hyperlipidemia and associated treatment patterns
among ﬁ ve European nations. METHODS: European Healthcare Panel of over 
160,000 individuals in France, Germany, Italy, UK and the Netherlands were surveyed
in 2007 to assess disease burden at national level, to build an epidemiological database
in these 5 countries. The data is representative of population gender and age 
(18–24,25–34,35–44,45–54,55–64,65–69 yrs) strata in respective countries, ensured
by sampling and intensive panel management. The survey collected information on
select health conditions (incl. hyperlipidemia, in terms of high cholesterol; in the
past 12-months), quality of life and health care-utilization. RESULTS: Prevalence of 
Hyperlipidemia varied widely between the 5 nations, as follows: Italy: 10.7%, the
Netherlands: 11.2%, U.K: 12.4%, France: 14.8%, Germany: 15.5%. Within each
country, burden of hyperlipidemia varied by age and gender; distribution among 
male (18–24,25–34,35–44,45–54,55–64,65yrs: % pts) was: Italy: 1.9%,3.1%,8.4%,
15.0%,18.2%,23.3; the Netherland: 0.6%,3.4%,5.9%,17.2%,25.6,24.6; U.K: 
1.6%,3.5%,9.0%,18.1%,28.7%,30.8; France: 1.9%,5.8%,13.4%,22.7%,29.4%,
28.2%; Germany: 2.3%,5.2%,13.1%,23.1%,27.9%,31.3%; distribution among 
female (18–24,25–34,35–44,45–54,55–64,65yrs: % pts) was: Italy: 2.4%,4.3%,6.6%,
12.4%,15.9%,30.3%; the Netherlands: 2.0%,2.6%,4.4%,12.2%,22.6%,30.4%; 
U.K: 1.2%,1.9%,4.8%,12.7%,23.7%,30.7%; France: 8.2%,7.6%,9.2%,15.1%,
23.5%,29.0%; Germany: 3.3%,5.8%,8.2%,16.5%,26.0%,31.1%. Point of diagnosis
varied across the countries: Italy: GP-52.7%,Specialist:20.3%,Hospital:22.8%,
Not-Medically-Diagnosed:4.2%; Netherlands: GP-57.9%,Specialist:22.9%,Hospital:
13.71%,Not-Medically-Diagnosed:5.4%; Germany: GP-76.1%,Specialist:16.0%,
Hospital:5.3%,Not-Medically-Diagnosed:2.6%; U.K: GP-79.0%,Specialist:6.6%,
Hospital:11.4%,Not-Medically-Diagnosed:3.0%; France: GP-83.3%,Specialist:9.2%,
Hospital:5.0%,Not-Medically-Diagnosed:2.6%. Majority were treated by their GPs
(range: 47.6% (Italy) to 72.4% (U.K)), followed by Specialists (range: 3.6% (U.K) 
to 20.1% (the Netherlands)). Being currently not medically treated was reported by
15.0%,15.7%,19.7%,20.0%,25.7% of individuals in Italy/U.K/France/the Nether-
lands/Germany respectively. Use of prescription medications predominated, while pre-
scription cost-reimbursement varied in the following order: fully-recompensated
(range: 18.3% (Germany) to 69.9% (UK)), with-co-payment (range: 0.0% (UK) to 
27.3% (Germany)) and complete-Out-of-Pocket (range: 0.0% (UK) to 12.1% (France)).
OTC product use very low (range: 0.8% (France) to 3.1% (Italy)). CONCLUSIONS:
Hyperlipidemia disease burden appear to be substantial and increased with age. Treat-
ment patterns and prescription cost reimbursement scenarios were diverse across the 
ﬁ ve European nations, with a sizable proportion remaining medically untreated.
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BURDEN OF HYPERTENSION AND ASSOCIATED TREATMENT PATTERNS 
IN EUROPE: A COMPARISON OF FIVE COUNTRIES
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany
OBJECTIVES: To assess hypertension disease burden and associated treatment 
patterns among ﬁ ve European nations. METHODS: A large multi-country online 
cross-sectional survey of over 160,000 adults was conducted in 2007 in France, 
Germany, Italy, UK and the Netherlands by TNS Healthcare. The survey enabled 
TNS to build an epidemiological database based on its proprietary European Health-
care Panel (EHP) of consumers in these 6 countries. The data is representative of 
population gender and age (18–24,25–34,35–44,45–54,55–64,65–69 yrs) strata in 
respective countries, ensured by sampling and intensive panel management. The survey 
collected information on select health conditions (incl. hypertension; in the past 12-
months), quality of life and health care-utilization. RESULTS: Hypertension disease 
prevalence varied widely between the 5 nations, as follows: France: 15.0%, Nether-
lands: 15.6%, U.K: 17.6%, Italy: 18.6%, Germany: 19.8%. Within each country, 
burden of hypertension increased with age, among both males and females; distribu-
tion among male (18–24,25–34,35–44,45–54,55–64,65yrs: % pts) was: France:
5.2%,6.0%,8.6%,18.6%,31.8%,36.4; the Netherlands: 1.3%,2.0%,9.3%,19.5%,
32.8%,36.0; U.K: 3.5%,5.9%,12.0%,22.8%,37.7%,43.6; Italy: 5.5%,5.8%,13.3%,
27.7%38.7%,43.6%; Germany: 7.0%,7.8%,14.4%,26.3%,38.3%,44.0%; distribu-
tion among female (18–24,25–34,35–44,45–54,55–64,65yrs: % pts) was: France:
5.5%,6.1%,8.5%,17.7%,27.8%,32.8%; the Netherlands: 2.0%,7.1%,10.9%,21.2%,
28.4%,34.8%; U.K: 5.0%,5.8%,9.6%,19.3%,29.2%,40.6%; Italy: 3.7%,4.0%,
8.3%,20.4%,28.6%,48.5%; Germany: 4.7%,5.3%,11.2%,22.7%,32.7%,37.7%. 
Point of diagnosis varied across the countries: Italy: GP-43.0%,Specialist:34.1%,
Hospital:17.7%,Not-Medically-Diagnosed:5.0%; Germany: GP-67.6%,Specialist:
22.3%,Hospital:6.1%,Not-Medically-Diagnosed:3.9%; Netherland: GP-69.8%,Spe-
cialist:17.2%,Hospital:8.6%,Not-Medically-Diagnosed:6.2%; France: GP-77.76%,
Specialist:12.7%,Hospital:5.9%,Not-Medically-Diagnosed:3.7%; U.K: GP-83.6%,
Specialist:4.8%,Hospital:7.9%,Not-Medically-Diagnosed:3.6%. Individuals were pri-
marily treated by their GPs (range: 49.4% (Italy) to 77.2% (U.K)), followed by 
Specialists (range: 2.8% (U.K) to 26.8% (Italy)). Being currently not medically 
treated was reported by 10.8%,11.6%,13.0%,15.1%,16.0% of individuals in Italy/
Germany/ France/U.K/Netherlands respectively. Use of prescription medications 
predominated, while prescription cost-reimbursement varied: fully-recompensated-
range: 31.0% (Germany) to 78.8% (Italy), with-co-payment- range: 0.0% (U.K) to 
51.1% (Germany) and complete-Out-of-Pocket- range: 0.0% (U.K) to 14.8% (France). 
CONCLUSIONS: Hypertension disease burden appear to be substantial and increased 
with age, accompanied by diverse treatment patterns and prescription cost reimburse-
ment scenarios across the ﬁ ve European nations.
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COMPARING CARDIOVASCULAR EVENT RATES OF STATIN PLUS
FIBRATE COMBINATION THERAPY WITH STATIN MONOTHERAPY
IN SUBJECTS WITH TYPE-2 DIABETES MELLITUS
Suh HS, Doctor JN
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To compare cardiovascular-event (CV) rates in subjects with type-2
diabetes who were on statinﬁ brate combination-therapy with those on statin-mono-
therapy in a managed care setting. METHODS: “Combo-group” (deﬁ ned as subjects
who used statinﬁ brate combination-therapy) and “mono-group” (deﬁ ned as subjects
who used statin-monotherapy) were identiﬁ ed among subjects with type-2 diabetes
having six-months washout-period without using any lipid-modifying agents, 2-years 
intake-period (July 1, 2002–June 30, 2004), 3-years follow-up, and treatment duration 
for more than 6-months using administrative claims from a Westcoast-based health 
